Development and validation of a bedside score to predict early death in cancer of unknown primary patients.

<h4>Background</h4>We have investigated predictors of 90-day-mortality in a large cohort of non-specific cancer of unknown primary patients.<h4>Methods</h4>Predictors have been identified by univariate and then logistic regression analysis in a single-center cohort comprising...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nicolas Penel, Sylvie Negrier, Isabelle Ray-Coquard, Charles Ferte, Patrick Devos, Antoine Hollebecque, Michael B Sawyer, Antoine Adenis, Pascal Seve
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2009
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2a93c6567a9443f396b3d2a0cf75cf43
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2a93c6567a9443f396b3d2a0cf75cf43
record_format	dspace
spelling	oai:doaj.org-article:2a93c6567a9443f396b3d2a0cf75cf432021-11-25T06:21:15ZDevelopment and validation of a bedside score to predict early death in cancer of unknown primary patients.1932-620310.1371/journal.pone.0006483https://doaj.org/article/2a93c6567a9443f396b3d2a0cf75cf432009-08-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19649260/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>We have investigated predictors of 90-day-mortality in a large cohort of non-specific cancer of unknown primary patients.<h4>Methods</h4>Predictors have been identified by univariate and then logistic regression analysis in a single-center cohort comprising 429 patients (development cohort). We identified four predictors that produced a predictive score that has been applied to an independent multi-institutional cohort of 409 patients (validation cohort). The score was the sum of predictors for each patient (0 to 4).<h4>Results</h4>The 90-day-mortality-rate was 33 and 26% in both cohorts. Multivariate analysis has identified 4 predictors for 90-day-mortality: performance status>1 (OR = 3.03, p = 0.001), at least one co-morbidity requiring treatment (OR = 2.68, p = 0.004), LDH>1.5 x the upper limit of normal (OR = 2.88, p = 0.007) and low albumin or protein levels (OR = 3.05, p = 0.007). In the development cohort, 90-day-mortality-rates were 12.5%, 32% and 64% when the score was [0-1], 2 and [3]-[4], respectively. In the validation cohort, risks were 13%, 25% and 62% according to the same score values.<h4>Conclusions</h4>We have validated a score that is easily calculated at the beside that estimates the 90-days mortality rate in non-specific CUP patients. This could be helpful to identify patients who would be better served with palliative care rather than aggressive chemotherapy.Nicolas PenelSylvie NegrierIsabelle Ray-CoquardCharles FertePatrick DevosAntoine HollebecqueMichael B SawyerAntoine AdenisPascal SevePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 4, Iss 8, p e6483 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Nicolas Penel Sylvie Negrier Isabelle Ray-Coquard Charles Ferte Patrick Devos Antoine Hollebecque Michael B Sawyer Antoine Adenis Pascal Seve Development and validation of a bedside score to predict early death in cancer of unknown primary patients.
description	<h4>Background</h4>We have investigated predictors of 90-day-mortality in a large cohort of non-specific cancer of unknown primary patients.<h4>Methods</h4>Predictors have been identified by univariate and then logistic regression analysis in a single-center cohort comprising 429 patients (development cohort). We identified four predictors that produced a predictive score that has been applied to an independent multi-institutional cohort of 409 patients (validation cohort). The score was the sum of predictors for each patient (0 to 4).<h4>Results</h4>The 90-day-mortality-rate was 33 and 26% in both cohorts. Multivariate analysis has identified 4 predictors for 90-day-mortality: performance status>1 (OR = 3.03, p = 0.001), at least one co-morbidity requiring treatment (OR = 2.68, p = 0.004), LDH>1.5 x the upper limit of normal (OR = 2.88, p = 0.007) and low albumin or protein levels (OR = 3.05, p = 0.007). In the development cohort, 90-day-mortality-rates were 12.5%, 32% and 64% when the score was [0-1], 2 and [3]-[4], respectively. In the validation cohort, risks were 13%, 25% and 62% according to the same score values.<h4>Conclusions</h4>We have validated a score that is easily calculated at the beside that estimates the 90-days mortality rate in non-specific CUP patients. This could be helpful to identify patients who would be better served with palliative care rather than aggressive chemotherapy.
format	article
author	Nicolas Penel Sylvie Negrier Isabelle Ray-Coquard Charles Ferte Patrick Devos Antoine Hollebecque Michael B Sawyer Antoine Adenis Pascal Seve
author_facet	Nicolas Penel Sylvie Negrier Isabelle Ray-Coquard Charles Ferte Patrick Devos Antoine Hollebecque Michael B Sawyer Antoine Adenis Pascal Seve
author_sort	Nicolas Penel
title	Development and validation of a bedside score to predict early death in cancer of unknown primary patients.
title_short	Development and validation of a bedside score to predict early death in cancer of unknown primary patients.
title_full	Development and validation of a bedside score to predict early death in cancer of unknown primary patients.
title_fullStr	Development and validation of a bedside score to predict early death in cancer of unknown primary patients.
title_full_unstemmed	Development and validation of a bedside score to predict early death in cancer of unknown primary patients.
title_sort	development and validation of a bedside score to predict early death in cancer of unknown primary patients.
publisher	Public Library of Science (PLoS)
publishDate	2009
url	https://doaj.org/article/2a93c6567a9443f396b3d2a0cf75cf43
work_keys_str_mv	AT nicolaspenel developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients AT sylvienegrier developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients AT isabelleraycoquard developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients AT charlesferte developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients AT patrickdevos developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients AT antoinehollebecque developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients AT michaelbsawyer developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients AT antoineadenis developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients AT pascalseve developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients
_version_	1718413794163556352

Development and validation of a bedside score to predict early death in cancer of unknown primary patients.

Ejemplares similares